Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings as a party. This amendment facilitates a reorganization under which Ligand's Merger Sub will merge with HoldCo, which will become a wholly owned subsidiary of Ligand. The change aims to streamline the acquisition process of XOMA Royalty.